Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of DirectorsGlobeNewsWire • 06/22/23
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory BoardGlobeNewsWire • 06/21/23
Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?Zacks Investment Research • 06/21/23
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The LancetGlobeNewsWire • 06/13/23
Valneva Announces the Availability of Documentation for its Shareholder MeetingGlobeNewsWire • 05/31/23
Valneva Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/04/23
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-FGlobeNewsWire • 03/31/23
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.GlobeNewsWire • 03/30/23
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising FutureSeeking Alpha • 03/30/23
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001GlobeNewsWire • 03/02/23
Valneva SE: Underfollowed French Biotech, 2 Interesting Vaccine Approvals Expected In 2023Seeking Alpha • 02/26/23
FDA Accepts Valneva's Chikungunya Vaccine License Application for Priority ReviewGlobeNewsWire • 02/20/23
Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease TestInvestors Business Daily • 02/17/23
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15GlobeNewsWire • 02/17/23
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 GuidanceGlobeNewsWire • 02/16/23
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 02/14/23
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccineGlobeNewsWire • 12/30/22